Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States
Journal of the American Heart Association · 07.07.2026 · 15 (13)
DOI: 10.1161/jaha.125.047135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 07.07.2026. Verfasst von Kevin M Alexander und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Stanford Amyloid Center Stanford University School of Medicine Stanford CA USA. Hauptthemen laut MEDLINE: Cardiomyopathies, Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Advances in diagnosis and disease awareness have led to increased prevalence and incidence of transthyretin amyloid cardiomyopathy (ATTR‐CM), but current US population‐based epidemiologic data are lacking. This study aimed to estimate temporal trends and current prevalence and incidence of ATTR‐CM in the United States and to describe patient characteristics and the clinical burden.
Methods
Data from the US Merative MarketScan Medicare Database (2010–2021) and the IQVIA PharMetrics Plus (2016–2023) claims database were assessed. An algorithm using codes for diagnoses and clinical drugs was used to identify patients with ATTR‐CM among individuals ≥18 years old. Incidence, prevalence, demographics, comorbidities, medication use, and clinical encounters were assessed annually in cross‐sectional cohorts.
Results
The incidence and prevalence of ATTR‐CM became higher over time, particularly in men and older age groups. The incidence per 100 000 person‐years was 44.3 (95% CI, 39.4–49.2) in 2021 for the Medicare Database (individuals aged ≥65 years) and 5.4 (95% CI, 5.0–5.8) in 2022 for PharMetrics Plus (individuals aged ≥18 years); the prevalence per 100 000 individuals was 95.8 (95% CI, 89.2–102.4) in 2022 in the Medicare Database and 11.3 (95% CI, 10.8–11.8) in 2023 in PharMetrics Plus. The number of comorbidities and medication use in the year before diagnosis increased over time; the number of clinical encounters in the year before diagnosis was relatively stable.
Conclusions
The incidence and prevalence of ATTR‐CM diagnoses have increased in the United States from 2010 to 2023, and the clinical burden among newly diagnosed individuals has become more complex.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Stanford Amyloid Center Stanford University School of Medicine Stanford CA USA.
- Indiana University School of Medicine Indianapolis IN USA.
- Novo Nordisk A/S Søborg Denmark.
- Cardiac Amyloidosis Program, Department of Medicine Columbia University Irving Medical Center, New York Presbyterian Hospital New York NY USA.
ORCID-Profile: Kevin M Alexander, Mathew S Maurer
Zitieren
APA
Alexander, K. M., Dasgupta, N. R., Mathisen, J., Møller, S. G., Tvistholm, A., & Maurer, M. S. (2026). Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States. Journal of the American Heart Association, 15(13). https://doi.org/10.1161/jaha.125.047135
Vancouver
Alexander KM, Dasgupta NR, Mathisen J, Møller SG, Tvistholm A, Maurer MS. Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States. Journal of the American Heart Association. 2026;15(13). doi:10.1161/jaha.125.047135
BibTeX
@article{Alexander2026,
author = {Alexander, Kevin M and Dasgupta, Noel R and Mathisen, Jimmi and Møller, Sidsel Gamborg and Tvistholm, Anders and Maurer, Mathew S},
title = {Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {13},
doi = {10.1161/jaha.125.047135}
}
EUVIMED